乙胺碘呋酮治疗心律失常临床观察

This paper presents a clinical study on the use of amiodarone administered orally in treating 21 patients with various cardiac arrhythmias resistant to conventional antiarrhythmic agents. The arrhythmias included atrial or ventricular premature systoles, paroxysmal supraventricular tachycardia, paroxysmal atrial fibrillation, sustained atrial fibrillation or flutter and paroxysmal transient ventricular tachycardia. Amiodarone was administered orally in doses of 200 mg three times daily during the initial 1～2 weeks. After the clinical effect was observed, a maintenance dose of 200 mg two times daily was given. From the begining of the third month the drug was withdrawn for two days every week. During the period of study no other antiarrhythmic agents were given to the patients. In this series, the antiarrhythmic effect of amiodarone proved to be excellent in 7 cases (33%),very good in 5 cases (24%), fairly good in 4 cases (19%) and poor or none in 5 cases (24%). The total effective rate of the entire series was 76%. Amiodarone appears to be effective for both atrial and ventricular arrhythmias, and may be given with safety except in cases of the sick sinus syndrome, in which the use of an artificial pacemaker is advisable before the drug is administered.